Table 2.
Trial | No. Patients | Chemotherapy | Radiation dose (Gy) | pCR | 3-yr survival |
---|---|---|---|---|---|
Le Prise et al.90 | |||||
Trimodality | 45 | Cisplatin, 5-FU | S, 20 | 9.8% | 19.2 |
Surgery | 41 | 13.8 NS | |||
Walsh et al.51 | |||||
Trimodality | 58 | Cisplatin, 5-FU | 40 Gy | 25% | 32 |
Surgery | 55 | 6 (P < .01) | |||
Bosset et al.91 | |||||
Trimodality | 143 | Cisplatin | SC, 37 Gy | 21% | 18.6 mos* |
Surgery | 139 | 18.6 mos* NS | |||
Urba et al.92 | |||||
Trimodality | 50 | Cisplatin, 5-FU, vinblastine | Hfx 45 Gy | 28% | 30 |
Surgery | 50 | 16 NS | |||
Lee et al.93 | |||||
Trimodality | 51 | Cisplatin, 5-FU | Hfx 45.6 Gy | 43% | 28.2* |
Surgery | 50 | 57* NS | |||
Burmeister et al.94 | |||||
Trimodality | 128 | Cisplatin, 5-FU | 35 Gy | 16% | 22.2 mos* |
Surgery | 128 | 27.3 mos* NS | |||
Tepper et al.52 | |||||
Trimodality | 30 | Cisplatin, 5-FU | 50.4 Gy | 40% | 39† |
Surgery | 26 | 16† (P = .002) |
All chemotherapy was given concurrently with radiotherapy unless specified.
Median survival
5-year survival
Abbreviations: S = sequential; SC = split course; Hfx = twice daily hyperfractionated; 5-FU = 5-fluorouracil; NS = not statistically significant